Acetophenazine

Summary

Acetophenazine (CHEMBL1085) is an approved small-molecule phenothiazine antipsychotic drug (ATC N05AB07); indicated across 1 condition including psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AB07
• Indications: 1 condition
• Chemistry: 411.6 Da · C23H29N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1085
Name	Acetophenazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	17676
ChEBI	CHEBI:2401
ATC	N05AB07
Molecular formula	C23H29N3O2S
Molecular weight	411.6
InChIKey	WNTYBHLDCKXEOT-UHFFFAOYSA-N

SMILES: CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO

IUPAC name: 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]ethanone

ChEBI definition: A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug.

Also known as: Acetofenazina, Acetophenazine, SID50125831, ACETOPHENAZINE, acetophenazine, ACETOPHENAZINE MALEATE

Parent form; salt/anhydrous children: CHEMBL2360079

Patent coverage: 1,337 distinct patent families (5,134 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,123 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Estrogen receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Motilin receptor, Sodium-dependent noradrenaline transporter.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	8.36	AC50	4.4	nM	CHEMBL_ACT_25193788
ADRA1A	8.35	AC50	4.5	nM	CHEMBL_ACT_25218260
HTR1A	8.15	AC50	7	nM	CHEMBL_ACT_25216205
DRD2	7.93	AC50	11.8	nM	CHEMBL_ACT_25140599
HRH1	7.31	AC50	49	nM	CHEMBL_ACT_25212778
ADRA2B	7.25	AC50	56	nM	CHEMBL_ACT_25143960
DRD1	7	AC50	100	nM	CHEMBL_ACT_25115863
ADRA2C	6.14	AC50	720	nM	CHEMBL_ACT_25148145
P15207	6.1	Ki	800	nM	CHEMBL_ACT_2149488
HTR2A	6.06	AC50	869.5	nM	CHEMBL_ACT_25225413
DRD1	5.95	AC50	1112	nM	CHEMBL_ACT_25181274
ADRA2A	5.92	AC50	1200	nM	CHEMBL_ACT_25220144
KCNH2	5.64	AC50	2300	nM	CHEMBL_ACT_25118243
HTR2B	5.35	AC50	4490	nM	CHEMBL_ACT_25227776

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).